Keratoacanthoma
☆ AI Dermatology — Free Service
2022 ۾ جرمني مان Stiftung Warentest نتيجن، ModelDerm سان صارفين جي اطمينان صرف ادا ڪيل ٽيلي ميڊيسن مشوري جي ڀيٽ ۾ ٿورو گهٽ هئي.
2022 ۾ جرمني مان Stiftung Warentest نتيجن، ModelDerm سان صارفين جي اطمينان صرف ادا ڪيل ٽيلي ميڊيسن مشوري جي ڀيٽ ۾ ٿورو گهٽ هئي.
عام Keratoacanthoma
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) هڪ بار بار ظاهر ٿيندڙ چمڙي جو ٽيمر آهي جيڪو پنهنجي جلدي واڌ ۽ پاڻ تي ٻيهر ٿيڻ جي صلاحيت سبب مشهور آهي. اهو عام طور تي پراڻي عمر وارن صاف چمڙي وارن مردن ۾ ٿئي ٿو، جن کي سورج جي نقصان جي تاريخ رکندڙ هوندا آهن. جڏهن ته excision يا Mohs micrographic سرجري استعمال ڪندي جراحي هٽائڻ عام علاج آهي، اتي مختلف علاج جا اختيار موجود آهن.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ھڪ گھٽ درجي جو ٽامِي آهي جيڪو چمڙي جي مخصوص غدود ۾ شروع ٿئي ٿو ۽ خوردبيني طور تي squamous cell carcinoma (SCC) جھڙو نظر اچي ٿو. هتي بحث جاري آهي ته ڇا KA کي ناگوار SCC جي شڪل ۾ درجه بندي ڪيو وڃي.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) ماڻهن ۾ سرطان جو ٻيو سڀ کان عام قسم آهي، خاص ڪري بزرگن ۾. جراحي عام طور تي cSCC جي علاج لاءِ استعمال ٿيندي آهي، پر ڪجهه مريض جيڪي سرجري نٿا ڪري سگهن يا نه چاهين، انهن لاءِ ٻيا اختيار جهڙوڪ اندروني علاج موجود آهن. روايتي اندروني علاج (methotrexate or 5-fluorouracil) استعمال ڪيا ويا آهن، پر نئين طريقن تي تحقيق جاري آهي جهڙوڪ intralesional immunotherapy ۽ oncolytic virotherapy. هتي، اسان cSCC لاءِ مختلف اندروني علاجن تي نظر وجهنداسين، ڪلاسيڪل طريقن کان وٺي جديد حڪمت عملين تائين.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
خوردبيني طور تي، keratoacanthoma اسڪواومس سيل ڪارڪينوما سان تمام ويجھو مشابهت رکي ٿو. جڏهن ته ڪجھ پيتھولوجسٽ ان کي الڳ وجود سمجهي درجه بندي ڪندا آھن، نه ته خرابي. تقريبن 6٪ ڪلينڪ ۽ هسٽولوجيڪل keratoacanthoma ناگوار ۽ جارحانه اسڪواومس سيل ڪينسر ڏانهن ترقي ڪندا آھن.
○ تشخيص ۽ علاج
#Dermoscopy
#Skin biopsy